Burning Rock Biotech (BNR) Return on Invested Capital (2022 - 2026)

Burning Rock Biotech's Return on Invested Capital history runs 5 years deep, the most recent figure standing at 1.15% for Q1 2026.

• In Q1 2026, Return on Invested Capital fell 3.5709420150055788e+16% year-over-year to 1.15%; the TTM figure through Mar 2026 stood at 1.15% (down 3.5709420150055788e+16% YoY), while the FY2021 annual figure was 3.5%, changed N/A from the prior year.
• Return on Invested Capital for Q1 2026 stood at 1.15%, up from 1.77% in the prior quarter.
• The five-year high for Return on Invested Capital was 1092334369348304.0% in Q3 2023, with the low at 13.94% in Q2 2025.
• The 5-year median for Return on Invested Capital is 0.83% (2022), against an average of 337508566884529.06%.
• The sharpest annual moves came in 2023 and 2025: Return on Invested Capital surged 2000000000 bps in 2023, then tumbled 2000000000 bps in 2025.
• Burning Rock Biotech's Return on Invested Capital stood at 2.7% in 2022, then jumped by 2000000000 bps to 1006630409117098.8% in 2023, then sank by 48 bps to 521914226117028.5% in 2024, then tumbled by 100 bps to 1.77% in 2025, then soared by 35 bps to 1.15% in 2026.
• Business Quant data shows BNR's Return on Invested Capital at 1.15% in Q1 2026, 1.77% in Q4 2025, and 5.82% in Q3 2025.